Evidence map›Paper›PMID 37187595›Full record

ArticleThe Pan African medical journal2023

Long-term evolution of immunological and virological parameters in patients undergoing treatments for HIV-1 infection at the Day Hospital of Bobo-Dioulasso, Burkina Faso.

Jessica Julie Chantal Samba, Yacouba Sawadogo, Herman Karim Sombie, Hervé Kafando, Wendinmi Arnaud Marie Joseph Zougmore, Maxime Damolga, Cheick Ahmed Ouattara, Armel Poda, Abdoul-Salam Ouedraogo

Open access · goldAbstract read
In one paragraph

Article in The Pan African medical journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jessica Julie Chantal SambaEmerging and Re-emerging Pathogens Laboratory, Sourô Sanou University Hospital Center, Bobo-Dioulasso, Burkina Faso.
Yacouba SawadogoEmerging and Re-emerging Pathogens Laboratory, Sourô Sanou University Hospital Center, Bobo-Dioulasso, Burkina Faso.
Herman Karim SombieEmerging and Re-emerging Pathogens Laboratory, Sourô Sanou University Hospital Center, Bobo-Dioulasso, Burkina Faso.
Hervé KafandoLaboratory Department, Dedougou Regional Hospital, Avenue of Governor Binger Dedougou, Burkina Faso.
Wendinmi Arnaud Marie Joseph ZougmoreEmerging and Re-emerging Pathogens Laboratory, Sourô Sanou University Hospital Center, Bobo-Dioulasso, Burkina Faso.
Maxime DamolgaEmerging and Re-emerging Pathogens Laboratory, Sourô Sanou University Hospital Center, Bobo-Dioulasso, Burkina Faso.
Cheick Ahmed OuattaraEmerging and Re-emerging Pathogens Laboratory, Sourô Sanou University Hospital Center, Bobo-Dioulasso, Burkina Faso.
Armel PodaEmerging and Re-emerging Pathogens Laboratory, Sourô Sanou University Hospital Center, Bobo-Dioulasso, Burkina Faso.
Abdoul-Salam OuedraogoEmerging and Re-emerging Pathogens Laboratory, Sourô Sanou University Hospital Center, Bobo-Dioulasso, Burkina Faso.
Nazi Boni University · BFCentre Hospitalier Universitaire Yalgado Ouédraogo · BFUniversité Joseph Ki-Zerbo · BF

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: antiretroviral therapy enables the suppression of the plasma viral load and the restoration of immune responses. Therapeutic failures are still observed in patients living with HIV despite the considerable benefits of antiretroviral therapy. This study aimed to describe the long-term evolution of immunological and virological parameters in patients undergoing treatments for HIV-1 at the Day Hospital of Bobo-Dioulasso in Burkina Faso. Methods: a retrospective descriptive and analytical study covering 10 years from 2009 was conducted at the Sourô Sanou University Hospital Center (CHUSS) in Bobo-Dioulasso. HIV-1-positive patients with at least two viral load measurements and two CD4 T cell counts were included in this study. Excel 2019 and RStudio were used to analyze the data. Results: a total of 265 patients were included in this study. The mean age of the patients was 48 ± 8.98 years and women accounted for 77.7% of the study population. A considerable decrease in the number of patients with TCD4 lymphocytes below 200 cells/μl from year 2 of treatment and a progressive increase in those with TCD4 lymphocytes above 500 cells/μl were observed in the study. Regarding the evolution of viral load, an increase in the proportions of patients with an undetectable viral load and a decrease in those with a viral load greater than 1000 copies/ml were noticed in years 2, 5, 6, and 8 of the follow-up. However, a decrease in the proportions of patients with undetectable viral load and an increase in those with viral load above 1000 copies/ml were observed in the years 4, 7, and 10 of follow-up. Conclusion: this study highlighted the different trends of viral load and LTCD4 evolution over 10 years of antiretroviral treatment. It showed a good immunovirological response was shown at the beginning of antiretroviral therapy, and then, a poor evolution of these markers at certain periods during the follow-up of HIV-positive patients.

Indexed as

HIV-1HIV InfectionsAdultBurkina FasoFemaleHospitals, UniversityHumansMiddle AgedRetrospective Studiesantiretroviral treatmentBurkina FasoImmunological markersvirological markers

Identifiers

PMID37187595
PMCPMC10175650
OpenAlexW4318822302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.